Two distinct subsets of CD4 + Foxp3 + regulatory T (Treg) cells have been described based on the differential expression of Helios, a transcription factor of the Ikaros family. Efforts to understand the origin and biological roles of these Treg populations in regulating immune responses have, however, been hindered by the lack of reliable surface markers to distinguish and isolate them for subsequent functional studies. (1, 2) . Although the significant contribution of Treg cells in the pathogenesis of autoimmunity has been established based on several animal models (3), investigations on exact pathogenic roles of Treg dysfunction in human autoimmune disorders have resulted in inconclusive findings, mainly due to the lack of specific markers that allow the reliable identification and isolation of a pure Treg population across donors. Most human studies rely on the high expression of CD25 and the low CD127 expression to identify Treg cells (4) . However, the expression levels of these two markers are modulated on conventional CD4 + T (Tconv) cells upon activation, making them indistinguishable from Treg cells during immune activation, thereby complicating the interpretation of findings based on these markers. Whereas the expression of FOXP3 can reliably identify human Treg cells in the resting state, its intracellular localization precludes its use for sorting of live cells. Moreover, TCR-mediated activation leads to a substantial upregulation of FOXP3 in a fraction of Tconv cells, thus confounding any ex vivo Treg phenotypic or functional analysis (5, 6) . To circumvent these issues and to characterize bona fide Treg cells, we previously used a single-cell cloning approach to dissect the functional heterogeneity within the FOXP3 + population of healthy individuals (7, 8) . We observed that the FOXP3 + T cell population, although composed mostly of highly suppressive Treg clones, contains a sizeable subpopulation (∼25-30%) of nonsuppressive FOXP3 + clones that are indistinguishable from their functional counterparts in terms of the conventional Treg markers (8) .
In the present study, we used the same single-cell cloning strategy to identify suppressive and nonsuppressive FOXP3 + Treg functional subsets in humans. We further performed microarray analysis to identify gene products that potentially discriminate these subsets. By comparing the gene expression profiles of these FOXP3 + Treg subsets, we found suppressive clones to have an Comparing suppressive and nonsuppressive clones, we also found an increased expression of the genes encoding two surface proteins: T cell immunoreceptor with Ig and ITIM domains (TIGIT) and FcR-like 3 (FCRL3). TIGIT is an immunoregulatory molecule expressed on memory and activated T cells (13) . Functionally, TIGIT has been reported to render dendritic cells (DCs) tolerogenic through interaction with its ligand (CD155) on DCs and induction of IL-10 production (13). TIGIT has also been shown to act as an intrinsic inhibitor of T cell proliferation, similar to the effect of CTLA-4 signaling (14) . Recently, Harrison and colleagues (15) showed that TIGIT is transcriptionally targeted by FOXP3, and a role for TIGIT signaling in enhancing Treg-mediated suppression has recently been suggested (16) .
FCRL3 (CD307c) is a member of the FCRL family of classical FcR homologs that is expressed on human B cells, some memory T lymphocytes, as well as NK cells (17, 18) . Although the ligand(s) and physiological function of FCRL3 on T cells are yet to be unraveled, the presence of both ITIM and ITAM motifs in its intracellular domain suggests a role for FCRL3 in the maintenance of homeostatasis via regulation of immune responses (19, 20) . Indeed, some studies have shown a potential role of FCRL3 in regulating B cell differentiation and proliferation initiated by BCR signaling (20, 21) . Interestingly, a functional variant in the FCRL3 promoter has been linked to susceptibility to rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and autoimmune thyroiditis (22) , and it was associated with increased expression of FCRL3 on T cells of RA patients (23) .
Examining the surface expression of TIGIT and FCRL3 on memory FOXP3
+ Treg cells, we found a positive correlation of both markers with Helios expression. We demonstrated that the simultaneous use of TIGIT and FCRL3 surface expression allows the consistent discrimination and isolation of live Helios + and Helios 2 memory FOXP3 + populations, each endowed with different functionalities. Notably, we demonstrate in the present study that TIGIT/FCRL3 is a stable marker combination under inflammatory conditions in vitro, in PBMCs of autoimmune patients, as well as in the resting state, thus providing a novel approach for further characterization of Treg heterogeneity in health and disease.
Materials and Methods

Donors and cell isolation
PBMCs were isolated from buffy coats of healthy donors (n = 11; Sanguine BioSciences) using Ficoll-Paque Plus density gradient (GE Healthcare) and cryopreserved. PBMC samples from untreated patients with relapsingremitting multiple sclerosis (n = 6), ulcerative colitis (n = 6), Crohn's disease (n = 6), and their age-and sex-matched healthy controls were obtained from the Montreal Neurological Institute as part of the Canadian Institutes for Health Research NET grant in clinical autoimmunity. PBMC samples from patients with active systemic lupus erythematosus (SLE; SLE Disease Activity Index 2000 update score of .6) were obtained from the Montreal General Hospital SLE clinic. All samples were collected in accordance with McGill University's Research Ethics Board.
Flow cytometry
For ex vivo flow cytometry analysis, PBMCs were thawed and stained with viability dye (eFluor 780; eBioscience). Purified anti-FCRL3 (24) was used where mentioned, followed by staining with F(ab9) 2 anti-mouse IgG (eFluor 660 or PE; eBioscience) and extensive washing with PBS. Cells were then stained with fluorochrome-conjugated Abs against CD4 (FITC or V500), CD25 (PE-CF594), CD45RA (Alexa Fluor 700) (BD Biosciences), CD127 (PE), TIGIT (PerCP-eFluor 710), FOXP3 (PE-Cy7), CD62L (FITC), HLA-DR (PE-Cy7), CTLA-4 (allophycocyanin) (eBioscience), and Helios (Pacific Blue; BioLegend).
For cytokine detection, PBMCs were incubated with PMA (25 ng/ml), ionomycin (1 mg/ml) (both from Sigma-Aldrich), and GolgiStop (eBioscience) for 4 h, followed by intracellular cytokine staining with Abs against IFN-g (FITC), IL-2 (PerCP-Cy5.5), and IL-17 (allophycocyanin) (eBioscience).
Flow cytometry analysis was performed on an LSRFortessa analyzer, and sorting throughout this study was performed on a FACSAria IIu cell sorter (both from BD Biosciences).
Generation of primary CD4 + clones
Primary CD4 + Treg and Tconv clones were generated from healthy PBMCs by single-cell expansion of FACS-sorted CD25 high (top 1%) and CD25 2 cells as described previously (7, 8) . The clones were expanded in X-VIVO 15 medium (Lonza) supplemented with 5% FBS (Sigma-Aldrich) and were stimulated with soluble anti-CD3 (30 ng/ml; eBioscience), recombinant human IL-2 (200 U/ml; gift of the Surgery Branch, National Cancer Institute, National Institutes of Health), and irradiated human PBMCs as feeders. Fresh medium and IL-2 were replenished on day 5 and every 2 d thereafter, and clones were passaged as needed. Restimulation was performed on days 11-12 and the clones were further expanded until harvested on days 22-24. Phenotypic and functional assays were performed on the clones in parallel. Clones were generated from seven different healthy subjects + clones/donor).
Suppression assays
CFSE-based suppression assays were used throughout this study to measure the suppressive potency of Treg cells as we previously described (8 
Gene expression analysis
Total mRNA was prepared from individual clones representing three populations: 1) suppressive and 2) nonsuppressive FOXP3 + clones generated from CD4 + CD25 high cells, and 3) control FOXP3 2 clones generated from CD4 + CD25
2 cells. The clones were derived from two healthy donors, and each group is represented by two to three pooled clones per donor. Clone selection was based on a thorough analysis of phenotype and function as we described before (8). Cells were pelleted and resuspended in RLT Plus lysis buffer (Qiagen) and immediately frozen at 280˚C. mRNA reverse transcription, labeling, and hybridization onto an Illumina HumanHT-12_V3 Expression BeadChip were performed by the Génome Québec Innovation Centre (Montreal, QC, Canada). The microarray data have been deposited in the National Center for Biotechnology Information's Gene Expression Omnibus and are accessible through Gene Expression Omnibus Series accession no. GSE65650 at: http://www.ncbi. nlm.nih.gov/geo/query/acc.cgi?acc=GSE65650.
Total gene expression data were normalized using the robust-spline method, without background correction and with base 2 logarithmic transformation, using the R software. Samples were compared using an Ftest (ANOVA) with the random variance model-based correction for multiple-hypothesis testing (25) using the R software. To minimize interference from gene expression of the irradiated feeders used to expand the clones, we established a feeder contamination standard curve by expanding the same clones in the presence of titrated numbers of feeder cells and processing the resulting samples on the same chip. For each gene expression value, the corresponding contamination contribution was predicted by regression, and a separate, corrected gene expression value was calculated. A gene was considered differentially expressed in two subsets when its corrected fold change value was $1.5 and the ANOVA p value was #0.1. 
TIGIT AND FCRL3 AS MARKERS OF HELIOS
T cell activation assays
To investigate the activation-induced modulation of marker expression, CD4 + CD25 2 TIGIT 2 FCRL3 2 cells from healthy PBMCs were FACS sorted, labeled with CFSE, and activated for 4-6 d in vitro with anti-CD3/ anti-CD28-coated beads (Miltenyi Biotec) at a ratio of two beads/one cell. Where indicated, irradiated autologous PBMCs were used as feeders. Protein expression levels of FOXP3, Helios, TIGIT, and FCRL3 were measured by flow cytometry over time. In different experiments, whole PBMCs were activated with anti-CD3/anti-CD28-coated beads for 3-5 d followed by flow cytometric analysis of marker expression.
Statistical analysis
Statistical analysis was performed using the GraphPad Prism 5.0 software. One-way ANOVA, followed by Turkey's range test, and the Student t test were used where indicated. A p value ,0.05 was considered significant.
Results
Lack of suppressive function in human FOXP3
+ clones is associated with reduced expression of Helios, TIGIT, and FCRL3
We have recently shown that in ∼30% of the FOXP3 + clones derived from healthy individuals, FOXP3 expression does not lead to suppressive function despite the maintenance of a typical Treg phenotype (8) (Fig. 1A) (Fig. 1C, 1D ). To further compare FPSP and FPSN clones, we analyzed the Tregspecific demethylated region (TSDR) of the FOXP3 locus, which is normally demethylated in Treg cells but methylated in Tconv cells (26, 27) . Owing to the female origin of the analyzed clones in this study, a Treg clone is expected to be ∼50% methylated in its TSDR region due to X chromosome inactivation (28) . Indeed, unlike FNSN clones, which have 77% methylated TSDR, both FPSP and FPSN clones show only ∼54% methylation in their TSDR regions (Supplemental Fig. 1 ), suggesting that both groups are derived from bona fide Treg cells.
However, several genes were found to be differentially expressed between the two FOXP3 + subsets (Fig. 1D, 1E ). One such gene, IKZF2, codes for the transcription factor Helios and was found to be significantly more transcribed in FPSP relative to FPSN clones (Fig. 1E) . Moreover, in search for potential extracellular markers of Treg functional subsets, we additionally found the genes coding for the surface receptors TIGIT and FCRL3 to be more highly expressed in FPSP clones relative to FPSN. The expression of all three genes was lowest in FNSN clones (Fig. 1E) .
To validate the differences observed in gene transcription, we generated primary clones from healthy individuals and examined the expression of FOXP3, Helios, TIGIT, and FCRL3 proteins in FPSP, FPSN, and FNSN clones. Whereas FOXP3 and TIGIT were expressed equally in FPSP and FPSN clones, both Helios and FCRL3 were significantly lower in FPSN relative to FPSP clones and lowest in FNSN clones (Fig. 2) (Fig. 3A, 3B) (Fig. 3B, 3C) . Conversely, the lack of both TIGIT and FCRL3 expression on memory FOXP3 + cells denotes a population that is predominantly negative for Helios (median, 17.1%; IQR, 5.48%). The ability to discriminate between Helios subsets was precisely reproducible in primary FOXP3 + clones derived from healthy individuals (Fig. 3D) 
FCRL3
2 subpopulation (Fig. 4A, 4B ). (Fig. 5C ). Moreover, we did not observe a significant change in the frequency of FCRL3 + or Helios + cells in the CD4 + population upon activation of healthy PBMCs (Supplemental Fig. 3 ), further indicating that both Helios and FCRL3 are not upregulated in Tconv cells upon activation. Finally, we examined the applicability of the TIGIT/FCRL3 combination for flow cytometric analysis of PBMCs derived from patients with various active autoimmune disorders, including untreated relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's disease, and active SLE. Similar to our observations in healthy subjects, the memory CD4 + CD25 + CD127 low cell population could be segregated into Helios + and Helios 2 subpopulations by further gating using TIGIT and FCRL3 (Supplemental Fig. 4A ). Collectively, these data indicate the stability of this marker combination in inflammatory conditions, and they provide a reliable approach for the consistent isolation of Treg cells. + cell subsets efficiently suppressed the proliferation of responder T cells, and no significant difference was observed between these subsets (Fig. 6A, 6B ). We then assessed whether FOXP3 + Treg cells that differentially express Helios displayed equivalent suppressive activities with prolonged T cell activation and expansion. To this end, we generated individual FOXP3 + clones from healthy PBMCs and assessed suppressive function relative to Helios expression (Fig. 6) . Our results show that the Helios 2 population contains a significantly higher proportion of nonsuppressive clones compared with its Helios + counterpart, although both populations harbored highly suppressive clones (Fig. 6D, 6E) .
Overall, our results show that differential TIGIT and FCRL3 expression on human FOXP3 + Treg cells can efficiently be used to isolate Helios-expressing subsets. Moreover, our data also indicate a greater level of functional heterogeneity within the Helios (29, 30) . However, the production of these cytokines has been observed in a small population of memory FOXP3 + cells (31, 32) . We analyzed cytokine production in healthy PBMCs ex vivo and found that, compared with FOXP3 2 cells, FOXP3 + cells are indeed poor producers of IFN-g, IL-17, and IL-2 in response to stimulation with PMA and ionomycin (Fig. 7B) . However, consistent with previous reports (10, 33), we detected a subpopulation of inflammatory cytokine-producing cells within the FOXP3 + population, and these cells were exclusively restricted to the Helios 2 subpopulation (Fig. 7A, 7B) . Similarly, increased levels of inflammatory cytokines were measured in FACS-sorted TIGIT (Fig. 7C) . Moreover, analysis of IFN-g, IL-17, and IL-2 production in CD4
low Treg cells of patients of several autoimmune diseases further confirms the restriction of cytokine production to the TIGIT 2
2 fraction of Treg cells (Supplemental Fig. 4B ). These data highlight important differences between Helios + and Helios 2 cells and emphasize the need for further characterization of their functional relevance. 
Discussion
The characterization of the relative function of Helios-defined Treg subsets has been hindered by the lack of reliable surface markers to delineate and isolate them. In this study, we identify the coexpression of TIGIT and FCRL3 as a novel marker combination that allows for a reliable stratification and isolation of human memory FOXP3 + Treg cells according to Helios expression. Importantly, we demonstrate the reliability of this marker combination under immune-activating conditions in vitro and in the periphery of autoimmune patients presenting with various active systemic and organ-specific autoimmune diseases. Moreover, our combined use of TIGIT and FCRL3 has enabled us to highlight significant functional differences between Helios + and Helios suppressive than Helios + cells. Note that the suppression assays in that study used monocytes as feeders and were stimulated with PHA, whereas the assays reported in the present study used irradiated PBMCs and were stimulated with soluble anti-CD3. Interestingly, our analysis of the suppressive capacity of FOXP3 (37, 38) , other studies suggest that some FOXP3 + Treg cells acquire a transient ability to produce IFN-g and IL-17 to allow efficient homing to Th1 and Th17 inflammation sites, respectively, without loss of suppressive function or downregulation of FOXP3 (8, 32, 39, 40) . We show that the expression of Helios in FOXP3 + cells correlates with a strong repression of effector cytokine production. These findings are in agreement with, and extend, recently reported observations that inflammatory cytokine production in human FOXP3 + cells is restricted to the Helios 2 population (10, 12, 33).
These results further highlight some potentially important functional differences between Helios + and Helios 2 Treg cells, and they warrant more in-depth analysis of the two subsets.
The degree of demethylation in the TSDR region of the FOXP3 promoter is now used as a measure of stability of FOXP3 ex- pression and suppressive function (26, 27 (16) found that TIGIT signaling enhanced Treg-mediated suppression of Th1 and Th17, but not of Th2, responses. Such selectivity is achieved through the production of fibrinogen-like protein 2, which prevents the suppression of Th2 responses. Other reported TIGIT-mediated regulatory functions include its active tolerogenization of DCs through binding to CD155 and induction of IL-10 secretion (13), as well as its intrinsic inhibition of T cell activation and proliferation (14) .
Two independent studies have previously examined the association between the expression of FCRL3 on Treg cells and their suppressive function. Whereas Swainson et al. (34) ). Statistical analysis was done with the one-way ANOVA followed by a Tukey posttest (B) or with the Student t test (C). *p # 0.05, ***p # 0.001. n.s., not significant.
